Table 2. Burden of off-target infections averted by annual ivermectin mass treatment with ivermectin in Africa.
Figures represent the cumulative burden averted between 1995 and 2010 in areas covered by the African Programme for Onchocerciasis Control.
| Burden averted by ivermectin mass treatment (DALYs x 1,000) a | ||||||||
|---|---|---|---|---|---|---|---|---|
| Country | Ascariasis | Trichur-iasis | Hook-worm | Strongy-loidiasis | Lymphatic filariasis | Scabies | Total | (%) |
| Angola | 0.2 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | 0.9 | (0.2%) |
| Burundi | 0.4 | 0.1 | 1.3 | 0.7 | 0.8 | 1.2 | 4.6 | (0.9%) |
| Cameroon | 23.6 | 6.1 | 5.7 | 7.2 | 8.5 | 8.0 | 59.3 | (12%) |
| Central African Republic | 0.5 | 0.2 | 4.3 | 0.3 | 2.6 | 3.0 | 10.9 | (2.2%) |
| Chad | 0.1 | 0.0 | 3.2 | 2.1 | 1.8 | 8.6 | 15.8 | (3.2%) |
| Congo | 1.5 | 0.8 | 0.6 | 0.5 | 0.8 | 0.8 | 5.1 | (1%) |
| Democratic Republic of Congo | 18.1 | 5.5 | 11.9 | 1.6 | 11.0 | 14.0 | 62.0 | (12.6%) |
| Equatorial Guinea | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.3 | (0.1%) |
| Ethiopia | 2.6 | 1.7 | 2.5 | 0.1 | 2.2 | 8.0 | 17.2 | (3.5%) |
| Liberia | 1.1 | 0.5 | 3.0 | 3.7 | 2.0 | 2.9 | 13.2 | (2.7%) |
| Malawi | 0.3 | 0.0 | 0.7 | 2.6 | 0.4 | 5.3 | 9.2 | (1.9%) |
| Nigeria | 112.0 | 1.2 | 20.5 | 45.3 | 31.8 | 49.1 | 259.9 | (52.8%) |
| Sudan and South Sudan b | 0.1 | 0.0 | 0.9 | 1.9 | 0.6 | 5.5 | 9.0 | (1.8%) |
| Uganda | 0.6 | 0.2 | 3.3 | 3.4 | 2.0 | 4.2 | 13.8 | (2.8%) |
| United Republic of Tanzania | 0.2 | 0.5 | 2.9 | 1.2 | 1.8 | 4.9 | 11.5 | (2.3%) |
| Total | 161.5 | 16.9 | 61.0 | 70.9 | 66.6 | 115.7 | 492.5 | (100%) |
a These figures are the product of the potential disease burden due to off-target infections in people treated with ivermectin and the assumed effect of ivermectin treatment on the disease burden (see Box 1).
b Estimates for Sudan and South Sudan are merged, as information on the burden per capita was reported for the two together [14].